In this study of administrative data from patients admitted to 421 U.S. hospitals with acute chronic obstructive pulmonary disease (COPD) exacerbations, 41% received long-acting bronchodilators, which are not recommended in this setting. Comparison with patients who did not receive the long-acting agents showed no evidence for clinical or economic benefit from their use.